RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Biotech Showcase 2022

13 slides from RespireRx Pharmaceuticals's conference presentation, Dec 14, 2021

  1. Slide 1: Biotech Showcase 2022 Presentation

    RespireRx Pharmaceuticals Inc Oye: ES BIOFECH SHOWCASE 2022 PRESENTATION January 2022

  2. Slide 2: Cautionary Notes: Forward Looking Statements

    CAUTIONARY NOTES WNQ RespireRx Pharmaceuticals Inc FORWARD LOOKING STATEMENTS This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21 of the Securities Exchange Act of 1934, as ame

  3. Slide 3: RespireRx is developing breakthrough drugs to modify neurotransmission

    * Neurons communicate through a process of neurotransmission in which they release chemical neurotransmitters that bind to specific receptors on adjacent neurons. RespireRx is developing breakthrough drugs to modify neurotransmission and create advanced treatments for disorders with high unmet needs

  4. Slide 4: Directly Acting Agonists/Antagonists and Neuromodulators

    Pharmaceuticals Inc Directly Acting Agonists/Antagonists ¢ Act directly at the neurotransmitter binding site to either stimulate (agonist) or interfere (antagonist) with the neurotransmitter receptor. NSare ESE * Cannabinoids, such as A9-THC, are direct agonists on the brain’s endocannabinoid recept

  5. Slide 5: Separate Business Units for Different Platforms

    Separate Business Units for Different Platforms HA RespireRx Pharmaceuticals Inc RespireRx Pharmaceuticals. Inc. (OTCQB:RSPI) *EndeavourRx *ResolutionRx Neuromodulators Pharmaceutical Cannabinoids *We are contemplating the reorganization as there are several advantages to separating these platforms

  6. Slide 6: Product Portfolio Summary

    Product Portfolio Summary WN RespireRx al ta Inc | EndeavourRx | | ResolutionRx { Neurom - Novel Brain Targeting Dru; Pharmaceutical Cannabinoids AMPAkines (AMPA Receptor Positive Allosteric Modulators) Dronabinol (49-THC) = 3 Successful phase 2A trials for CX1739 and CX717 " Treatment of Obstructiv

  7. Slide 7: RespireRx - Product Development Status

    RespireRx - Product Development Status DB RespireRx Pharmaceuticals Inc Preclinical Phase 1 Phase 2 Phase 3 ResolutionRx - Cannabinoids Dronabinol — OSA —— Dronabinol Formulation == EndeavourRx - Neuromodulators AMPAkKines CX717 - ADHD Sp CX1739-Spinal Cord Injury CX1942 —follow-up compound =a GABAk

  8. Slide 8: Intellectual Property

    Intellectual Property WN RespireRx al ta Inc | EndeavourRx | | ResolutionRx | AMPAKines Dronabinol (49-THC) = Broad family of patents = License to issued method-of-use patent in the US, UK and Germany for the use of dronabinol for , 2 —_— treating OSA (expires 2025 in U.S.) = Patent longevity: compo

  9. Slide 9: Global Market Opportunities

    Global Market Opportunities WN RespireRx | EndeavourRx | AMPAKines SCI (Spinal Cord Injury): = Estimated 288,000 patients in US; $ multi-100 million market ADHD (Attention Deficit Hyperactivity Disorder): = Multi$ billion market, dominated by habit-forming scheduled drugs GABAkines Epilepsy: = § mul

  10. Slide 10: RespireRx - Organizational Structure

    RespireRx - Organizational Structure HA Resp ireRx Pharmaceuticals Inc 10

  11. Slide 11: Short-Term Milestones

    Short-Term Milestones NQ RespireRx dhe Inc | EndeavourRx | | ResolutionRx | AMPAkines Dronabinol (A9-THC) = PK studies with new formulation Initiate SCI phase 2A studies Patent filings = Patent filings = Pre-IND meeting with FDA GABAKIIE® = Phase 3 design completion = Complete pre-clinical developme

  12. Slide 12: Corporate Summary

    Corporate Summary RQ RespireRx See ce Inc v Highly desirable assets — advancing clinical programs and patent estate v Diverse portfolio of novel products across multiple therapeutic categories and indications v Broad flexibility in identifying unique investment structures v Strategic partners afford

  13. Slide 13: RSE

    RSE TA CtS. rut OTCQB 6 9) Pharmaceuticals Inc

RespireRx Pharmaceuticals — Biotech Showcase 2022 on 6ix